| name | endo-fha-avoid-ocps-menses-bmd |
| description | This skill advises against prescribing oral contraceptive pills solely to induce menstruation or enhance bone mineral density in patients with functional hypothalamic amenorrhea (FHA). Use when a clinician considers, 'Should I give her OCPs to get her period back?' or encounters statements such as 'Don’t use OCPs just for menses' or 'Avoid OCPs as a sole BMD strategy'. |
Avoid using oral contraceptive pills solely to regain menses or improve BMD
STEP 1 — Gather Information
Collect detailed history of weight changes, exercise intensity, stressors, menstrual pattern, pregnancy status, and obtain baseline BMD by DXA if amenorrhea ≥6 months or if there is suspicion of severe nutritional deficiency/skeletal fragility; if FHA is suspected after excluding pregnancy and anatomic causes, proceed to Step 2.
STEP 2 — Rule In / Rule Out
Exclude pregnancy, anatomic outflow tract abnormalities, and other endocrine disorders (thyroid, prolactin, androgen excess) using appropriate labs and imaging; if no organic cause is found and FHA criteria are met, rule in FHA and move to Step 3; otherwise, manage the identified etiology.
STEP 3 — Classify or Stratify
Determine the primary intent behind OCP request: if the sole goal is to regain menses or improve BMD, classify as non‑contraceptive use; if contraception is needed, classify as contraceptive use and note that OCPs may be appropriate for that purpose; if non‑contraceptive use, proceed to Step 4 to avoid OCPs.
STEP 4 — Decide
Do not prescribe OCPs solely for menses or BMD improvement; instead implement a multidisciplinary plan to correct energy imbalance (increase caloric intake, reduce excessive exercise, address stressors) and offer psychological support such as CBT; if bone health is a concern and estrogen deficiency persists, consider transdermal estradiol with cyclic oral progestin (not OCPs) and schedule follow‑up BMD and clinical review.
Clinical Guardrails / Mimics / Pitfalls
OCPs can mask the return of spontaneous menses, giving false reassurance of recovery; bone loss may continue if an energy deficit persists because OCPs downregulate IGF‑I, a bone‑trophic hormone; avoid using OCPs as a sole strategy for BMD improvement in FHA.
Concrete Clinical Example
A 22‑year‑old distance runner presents with 8 months of amenorrhea, BMI 17.5 kg/m², and asks for OCPs to “get her period back.” After confirming FHA (negative pregnancy, normal TSH/prolactin, low estradiol), the clinician advises against OCPs for menses alone, recommends a 300‑kcal/day increase, reduction of running mileage, weekly CBT, and obtains a baseline DXA (Z‑score –1.2). At 3‑month follow‑up, weight has increased to 18.8 kg/m² and menses have resumed without OCPs.
Source: Functional Hypothalamic Amenorrhea: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2017, https://doi.org/10.1210/jc.2017-00131
